TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00730743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver
Description: Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
Study: NCT01061489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auditory discrimination training
Description: 10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical movement training
Description: 10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
Study: NCT00883753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
Study: NCT03267355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Indication of EUS
Study: NCT04332419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Standard Imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Additional Imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIRT with Y-90
Description: SIRT with Y-90 for palliative treatment of the liver malignancy.
Study: NCT04457440

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Lifestyle Intervention
Description: This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention
Description: This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
Study: NCT04934735

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program group
Description: The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned.
Study: NCT02493751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
Study: NCT00375245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin (sirolimus)
Description: Weekly oral doses, dose is assigned at the time of study entry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit Juice
Description: Daily oral doses starting during the second week on study.
Study: NCT00432198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem (Myslee®)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem (Myslee®)
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral
Study: NCT03195140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Suspend
Description: Application of Predictive Low Glucose Suspend
Study: NCT00677950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal fusion
Description: Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
Study: NCT04638179

Intervention type: OTHER
Intervention: Not intervention.Use retrospective case contrl study.
Description: Use retrospective case contrl study.
Study: NCT05374876

Intervention type: OTHER
Group type: OTHER
Intervention: Hand Therapy Until CIPN
Description: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand Therapy Until CIPN
Description: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
Study: NCT00719602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Taken orally twice daily
Study: NCT02787876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegteograstim
Study: NCT00677950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal fusion
Description: Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
Study: NCT02515669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7239361
Description: Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Study: NCT02072577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
Study: NCT03785301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre Flash Glucose Monitoring
Description: Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
Study: NCT00719602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Taken orally twice daily
Study: NCT02515669

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Study: NCT03731130

Intervention type: OTHER
Intervention: EORTC QLQ C30
Description: standardized questionaire
Study: NCT01850810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study Product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Study Product
Study: NCT02334709

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
Study: NCT00393822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one bolus IV injection at 120 μg/kg/day of matched placebo
Study: NCT02158494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance and Gait Training using neurostimulation modulation.
Description: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
Study: NCT01673685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Oxygen
Study: NCT03974217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
Study: NCT03737981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01265537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.
Study: NCT03878849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2X-121
Description: Every patient will receive daily oral administrations of 3 x 200 mg 2X-121 hard gelatin capsules in a 28-day cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2X-121 DRP®
Description: A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
Study: NCT01673685

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Portable Oxygen
Study: NCT02594358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
Study: NCT03835715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
Study: NCT00920543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily dosing
Study: NCT00958451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.
Study: NCT04435197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pre-operative Pembrolizumab+chemoradiotherapy
Study: NCT03731130

Intervention type: OTHER
Intervention: EORTC QLQ C30
Description: standardized questionaire

Intervention type: OTHER
Intervention: EORTC QLQ CR29
Description: standardized questionaire
Study: NCT04576234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: entral feeding
Description: Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: entral feeding
Description: Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
Study: NCT03354286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental & Technological Demands
Description: Education and training related to use of CGM in this age group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Reduction
Description: Education and training on reducing distress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition, Set Point, & C:I Ratio
Description: Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoglycemia management
Description: Education and training on reducing worries of hypoglycemia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal Intervention
Description: Minimal intervention to simulate standard care - serves as the control group
Study: NCT00002939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01845272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
Study: NCT00920543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 500mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 250mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 100/50mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 250/50mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 500/50mcg
Description: Twice daily dosing
Study: NCT00003789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isolated limb perfusion
Description: Undergo isolated limb perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isolated limb perfusion
Description: Undergo isolated limb perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given via limb perfusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant tumor necrosis factor family protein
Description: Given via slow injection into the arterial line

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03420677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of tones
Description: During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No application of tones
Description: This is the sham-control intervention; The device will only record biosignals but will not play tones.
Study: NCT03901963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
Study: NCT03555851

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.

Intervention type: OTHER
Intervention: Specimen collection
Description: Buccal swabs will be obtained from donors for pharmacogenomics.

Intervention type: OTHER
Intervention: Specimen collection
Description: Buccal swabs will be obtained from donors for pharmacogenomics.
Study: NCT02306161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV